ADMA Biologics manufactures FDA-approved biologics.
5 reports, 2 independent
Updated Jul 29
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 3
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ADMA Biologics manufactures FDA-approved biologics.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- ASCENIV is identified as ADMA Biologics' flagship immunoglobulin product.Sub-event
ADMA Biologics has received FDA approval for its biologics.1 source
FDA approval supports production yields for ADMA Biologics.1 source
Keep exploring
The entities involved
- FDA
-
ADMA Biologics (United States)
company in Ramsey, United States
Nothing else this week.
Related events
- The FDA indicated on June 25, 2025, that an Advisory Committee (AdCom) was not necessary for a specific review.
- A product was launched in the U.S. market following FDA involvement.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
Coverage
Newest first; wire copies grouped- GlobeNewswireADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE
- Simply Wall St.High Growth Tech Stocks In The US To Watch This July 2025 The United States market has experienced a 1.4% increase over the past week and is up 17% over the last year, with earnings anticipated to gr
- Unknown outlet
- Unknown outlet